GO:0045031 G protein-coupled ATP receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045031 (G protein-coupled ATP receptor activity) describes a molecular function in which extracellular ATP binds a G protein-coupled receptor (GPCR) and activates heterotrimeric G proteins by promoting GDP-to-GTP exchange on the alpha subunit.
• The best-characterized human GPCRs with ATP-activated, G protein-coupled activity are the P2Y receptors, especially P2Y11 (P2RY11), P2Y6 (P2RY6), P2Y13 (P2RY13), and related purinergic GPCRs [2,3,5,6].
• P2Y11 is a human G protein-coupled ATP receptor linked to IL-10-driven macrophage differentiation and anti-inflammatory signaling, making it a candidate target for inflammatory disease research [2,3].
• P2Y6 and CYSLTR2 can sense ceramides and contribute to atherosclerosis, showing that ATP/ceramide-sensing GPCRs participate in vascular pathology.
• P2RY13 exacerbates intestinal inflammation by damaging the mucosal barrier through the IL-6/STAT3 pathway, linking this receptor class to gut inflammatory disease.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal testing of P2Y receptor genes in inflammation, atherosclerosis, liver disease, and infectious disease [1,4,5,8].
Description
GO:0045031, G protein-coupled ATP receptor activity, is a molecular function defined by the binding of extracellular ATP to a G protein-coupled receptor (GPCR) and transmission of that signal across the membrane through activation of an associated heterotrimeric G protein, promoting exchange of GDP for GTP on the G-alpha subunit. This function sits at the intersection of purinergic signaling and classical GPCR biology, and it is best represented in humans by the P2Y family of ATP-responsive receptors. Purinergic GPCRs allow cells to sense extracellular nucleotides released during stress, inflammation, platelet activation, and tissue injury, converting ATP gradients into intracellular second-messenger responses [5,6]. Because ATP is abundant intracellularly but appears extracellularly under specific physiological and pathological conditions, receptors with this activity act as context-dependent sensors rather than simple on/off switches. The importance of GO:0045031 extends across immunology, vascular biology, hepatology, and infectious disease, where P2Y receptors shape cytokine production, barrier integrity, and inflammatory cell recruitment [1,2,4,5,8]. For researchers, this term provides a precise functional annotation for genes whose protein products bind ATP and signal through G proteins, distinguishing them from ionotropic ATP receptors and from ATP-binding enzymes. Understanding this activity at the level of specific genes, receptor subtypes, and downstream pathways is essential for target validation in inflammation and metabolic disease [3,5].
G protein-coupled ATP receptor activity At A Glance
| GO ID | GO:0045031 |
|---|---|
| GO term | G protein-coupled ATP receptor activity |
| Ontology | molecular_function |
| Synonym | ATP-activated adenosine receptor activity; ATP-activated nucleotide receptor activity |
| Major function | Binds extracellular ATP and activates heterotrimeric G proteins by promoting GDP-to-GTP exchange on the G-alpha subunit |
| Representative genes | P2RY11, P2RY6, P2RY13, and related purinergic GPCRs [2,3,4,5,6] |
| Signaling class | G protein-coupled receptor (GPCR) / purinergic P2Y receptor family |
| Key downstream themes | IL-10-driven macrophage differentiation, IL-6/STAT3 signaling, ceramide sensing, vascular and mucosal inflammation [1,2,3,4] |
| Disease relevance | Atherosclerosis, intestinal inflammation, liver pathophysiology, infectious disease, inflammatory conditions [1,4,5,8] |
What Is GO:0045031?
In plain terms, GO:0045031 describes what happens when ATP outside a cell docks onto a G protein-coupled receptor and flips a molecular switch inside the cell. The QuickGO definition states that this activity combines with ATP and transmits the signal across the membrane by activating an associated G protein, promoting the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G protein complex. This places the function within the molecular_function ontology, with synonyms including ATP-activated adenosine receptor activity and ATP-activated nucleotide receptor activity. Unlike ATP-gated ion channels, which directly open a pore, receptors with this activity work through heterotrimeric G proteins and downstream effectors. The defining biochemical event is nucleotide exchange on G-alpha, which converts the receptor from an inactive to an active signaling state.
Why Is G protein-coupled ATP receptor activity Important in Cell Biology?
GO:0045031 matters because it defines a specific, druggable signaling function that converts extracellular ATP into intracellular G protein signals, and this function is increasingly implicated in human inflammatory and metabolic disease [3,5]. The human G protein-coupled ATP receptor P2Y11 has been associated with IL-10-driven macrophage differentiation and proposed as a target for anti-inflammatory strategies, indicating that this activity can shape immune cell fate rather than merely trigger acute signaling [2,3]. Related receptors such as P2RY13 and P2RY6 contribute to intestinal inflammation and atherosclerosis, respectively, showing that the same functional class participates in distinct organ-level pathologies [1,4]. In infectious disease contexts, G protein-coupled purinergic P2Y receptors modulate host responses, making this activity relevant to infection and inflammation research. In the liver, purinergic signaling participates in pathophysiological processes, further broadening the disease scope of this term. Because the function is defined by a precise biochemical event, GDP-to-GTP exchange on G-alpha, it is amenable to mechanistic dissection using CRISPR-engineered cell models and pathway-specific assays.
• Defines a precise molecular function that distinguishes G protein-coupled ATP receptors from ionotropic ATP receptors and ATP-binding enzymes.
• Provides a functional annotation framework for P2Y receptor genes such as P2RY11, P2RY6, and P2RY13 in inflammation research [2,3,4].
• Links extracellular ATP sensing to immune cell differentiation, including IL-10-driven macrophage polarization.
• Supports anti-inflammatory target discovery, as P2Y11 has been proposed as a target for anti-inflammatory strategies.
• Connects purinergic GPCR signaling to atherosclerosis through ceramide sensing by CYSLTR2 and P2RY6.
• Implicates this activity in intestinal mucosal barrier damage via IL-6/STAT3 signaling downstream of P2RY13.
• Highlights relevance to infectious disease through G protein-coupled purinergic P2Y receptor biology.
• Extends to liver pathophysiology, where purinergic signaling contributes to disease processes.
• Enables causal gene-function studies using CRISPR knockout, point mutation, knock-in, and overexpression models [1,4].
• Supports pharmacology and drug discovery because GPCRs are tractable small-molecule targets.
What Happens During G protein-coupled ATP receptor activity?
ATP binding to the receptor
In simple terms: ATP outside the cell fits into a pocket on the receptor, like a key in a lock.
The function begins when extracellular ATP binds a G protein-coupled receptor, typically a purinergic P2Y receptor, at a site that confers nucleotide selectivity. This binding event is the defining trigger for GO:0045031 and distinguishes ATP-activated GPCRs from receptors activated by other ligands. Purinergic signaling depends on controlled release of ATP into the extracellular space, where it can act on these receptors. The receptor must be in a conformation competent to couple to a heterotrimeric G protein for signaling to proceed.
G protein activation and GDP-to-GTP exchange
In simple terms: The receptor flips a molecular switch on a partner protein, turning the signal on inside the cell.
Upon ATP binding, the receptor acts as a guanine nucleotide exchange factor for the associated heterotrimeric G protein, promoting release of GDP and binding of GTP on the G-alpha subunit. This GDP-to-GTP exchange is the core biochemical event specified by the GO definition and is the point at which the signal crosses the membrane. Activated G-alpha-GTP then dissociates from G-beta-gamma dimers and engages downstream effectors. The specificity of downstream signaling depends on the G-alpha subtype coupled to the receptor.
Downstream effector and second-messenger signaling
In simple terms: Once switched on, the G protein tells other proteins inside the cell what to do.
Activated G proteins regulate effector enzymes and channels that produce second messengers, amplifying the initial ATP signal. In immune cells, this activity can shape cytokine programs; P2Y11 has been associated with IL-10-driven macrophage differentiation. In intestinal inflammation, P2RY13 signaling activates the IL-6/STAT3 pathway and damages the mucosal barrier. In vascular pathology, ceramide sensing by CYSLTR2 and P2RY6 aggravates atherosclerosis, illustrating how this functional class translates ligand sensing into tissue-level disease.
Signal termination and regulation
In simple terms: The signal is switched off when ATP is removed or the receptor is desensitized.
Extracellular ATP is rapidly degraded by ectonucleotidases, terminating receptor occupancy and downstream G protein signaling [5,6]. GPCR desensitization and internalization provide additional layers of negative regulation common to this receptor class. Because the activity depends on both ligand availability and receptor coupling, its intensity is set by the balance of ATP release, degradation, and receptor surface expression. Pharmacological tools that target P2Y receptors can modulate this activity and are useful for dissecting its contribution to disease.
Key Genes Involved in GO:0045031 G protein-coupled ATP receptor activity
The following genes encode receptors or pathway components most directly associated with G protein-coupled ATP receptor activity and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| P2RY11 | Human G protein-coupled ATP receptor linked to IL-10-driven macrophage differentiation | Target for anti-inflammatory strategies and immune cell fate studies [2,3] |
| P2RY6 | Purinergic GPCR implicated in ceramide sensing and atherosclerosis | Vascular inflammation and ceramide signaling research |
| P2RY13 | Purinergic GPCR that activates IL-6/STAT3 and damages intestinal mucosal barrier | Intestinal inflammation and barrier function studies |
| CYSLTR2 | GPCR that can sense ceramides together with P2RY6 in atherosclerosis | Atherosclerosis and lipid-sensing GPCR research |
| P2RY1 | Purinergic P2Y receptor family member | General P2Y receptor pharmacology and signaling studies |
| P2RY2 | Purinergic P2Y receptor family member | General P2Y receptor pharmacology and signaling studies |
| P2RY4 | Purinergic P2Y receptor family member | General P2Y receptor pharmacology and signaling studies |
| P2RY12 | Purinergic P2Y receptor family member | Platelet and purinergic signaling research |
| P2RY14 | Purinergic P2Y receptor family member | Purinergic signaling and inflammation research |
| GNAQ | G-alpha subunit that can couple to GPCRs | Downstream G protein signaling dissection |
| GNAI1 | G-alpha inhibitory subunit | GPCR coupling and second-messenger studies |
| GNAS | G-alpha stimulatory subunit | GPCR coupling and cAMP pathway studies |
| GNA12 | G-alpha 12 family subunit | GPCR-mediated Rho signaling studies |
| GNA13 | G-alpha 13 family subunit | GPCR-mediated Rho signaling studies |
| STAT3 | Transcription factor downstream of IL-6 signaling in intestinal inflammation | P2RY13-IL-6/STAT3 axis research |
| IL6 | Cytokine linked to mucosal barrier damage downstream of P2RY13 | Intestinal inflammation models |
| IL10 | Anti-inflammatory cytokine associated with P2Y11-driven macrophage differentiation | Macrophage polarization and inflammation studies |
How Is G protein-coupled ATP receptor activity Regulated?
G protein-coupled ATP receptor activity is regulated at multiple levels. Ligand availability is controlled by extracellular ATP release and degradation by ectonucleotidases, which determines how long receptors remain occupied [5,6]. Receptor coupling to heterotrimeric G proteins determines which downstream effectors are engaged, and the identity of the G-alpha subunit shapes the response. In immune contexts, P2Y11 activity is associated with IL-10-driven macrophage differentiation, indicating that the functional outcome of this activity is integrated with cytokine networks. In intestinal inflammation, P2RY13 signaling activates the IL-6/STAT3 pathway, providing a specific downstream regulatory axis. In vascular pathology, ceramide sensing by CYSLTR2 and P2RY6 modulates atherosclerosis, showing that lipid ligands and ATP-sensing GPCRs can converge on disease-relevant regulation. General GPCR regulatory mechanisms such as desensitization and internalization also apply to this receptor class.
G protein-coupled ATP receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| P2RY6 / CYSLTR2 | Atherosclerosis and ceramide sensing | Knockout and overexpression in vascular/immune cells |
| P2RY13 | Intestinal inflammation and mucosal barrier damage | Intestinal epithelial knockout and IL-6/STAT3 reporter models |
| P2RY11 | IL-10-driven macrophage differentiation and inflammation | Macrophage knockout and overexpression models [2,3] |
| P2Y receptor family | Infectious disease and host response | Immune cell knockout and infection challenge models |
| Purinergic signaling genes | Liver pathophysiology | Hepatocyte knockout and overexpression models |
Atherosclerosis and vascular inflammation
G protein-coupled ATP receptor activity contributes to vascular pathology through purinergic and lipid-sensing GPCRs. CYSLTR2 and P2RY6 can sense ceramides and aggravate atherosclerosis, linking this functional class to plaque-promoting inflammation. These findings position ATP/ceramide-responsive GPCRs as contributors to vascular disease and as candidates for mechanistic studies in endothelial and immune cell models.
Intestinal inflammation and mucosal barrier damage
P2RY13 exacerbates intestinal inflammation by damaging the intestinal mucosal barrier via activation of the IL-6/STAT3 pathway. This connects G protein-coupled ATP receptor activity to gut inflammatory disease and identifies a specific receptor-to-cytokine axis that can be tested in epithelial and immune cell models.
Inflammation and immune cell differentiation
The human G protein-coupled ATP receptor P2Y11 is associated with IL-10-driven macrophage differentiation and has been proposed as a target for anti-inflammatory strategies [2,3]. This indicates that this activity can shape immune cell fate and inflammatory resolution, making it relevant to chronic inflammatory conditions [2,3].
Infectious disease and liver pathophysiology
G protein-coupled purinergic P2Y receptors participate in infectious disease responses, and purinergic signaling is implicated in liver pathophysiology [5,8]. These broader contexts show that ATP-sensing GPCR activity is not restricted to a single organ system but contributes to host-pathogen interactions and hepatic disease processes [5,8].
From G protein-coupled ATP receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of P2RY11 alter macrophage differentiation? | P2RY11 knockout macrophage cell line [2,3] |
| Does P2RY13 drive IL-6/STAT3-dependent barrier damage? | P2RY13 knockout intestinal epithelial cells with STAT3 readout |
| Do P2RY6 and CYSLTR2 mediate ceramide sensing in atherosclerosis? | P2RY6/CYSLTR2 knockout and overexpression vascular cell models |
| Which G-alpha subunit couples to an ATP-responsive GPCR? | Point-mutation or knock-in of G-alpha coupling interface |
| Can receptor overexpression amplify downstream second messengers? | Overexpression cell model with pathway reporters |
| Does a candidate receptor contribute to infectious disease responses? | Knockout immune cells in infection challenge assays |
How to Study the G protein-coupled ATP receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| G protein activation assay | GDP-to-GTP exchange or G-alpha activation | Confirming GO:0045031 activity for a candidate receptor |
| Second-messenger assay | cAMP, calcium, or other downstream signals | Assigning coupling and pathway output |
| CRISPR knockout | Requirement of a specific gene for the response | Testing P2RY11, P2RY13, P2RY6 causality [2,3,4] |
| Overexpression | Sufficiency of a receptor to drive signaling | Amplifying receptor activity in cell models |
| RNA sequencing | Transcriptional programs downstream of receptor activation | Identifying cytokine and STAT3 target programs |
| Macrophage differentiation assay | IL-10-driven polarization states | Studying P2Y11 in immune cell fate |
| Barrier integrity assay | Mucosal barrier function | Testing P2RY13 effects in intestinal cells |
| Vascular inflammation model | Atherosclerosis-related inflammatory readouts | Studying P2RY6/CYSLTR2 ceramide sensing |
Pharmacological and second-messenger assays
Because GO:0045031 is defined by G protein activation, assays that measure G-alpha nucleotide exchange or downstream second messengers are central. P2Y receptor pharmacology provides tools to activate or block these receptors and to assign coupling specificity. Such assays can be combined with ATP dose-response experiments to confirm that a candidate receptor has ATP-activated, G protein-coupled activity.
CRISPR-based causal testing
Knockout of candidate P2Y receptor genes followed by ATP stimulation allows researchers to test whether a specific gene is required for the observed signaling response [2,3,4]. This approach has been used to link P2RY13 to IL-6/STAT3 activation and mucosal barrier damage, and to study P2RY11 in macrophage differentiation [2,4]. Overexpression and knock-in models complement knockout by testing sufficiency and by introducing specific receptor variants.
Transcriptomic and pathway readouts
RNA sequencing and pathway-focused readouts can identify downstream programs controlled by G protein-coupled ATP receptor activity, such as cytokine and STAT3 target genes. In immune cells, this can reveal shifts in macrophage polarization states associated with P2Y11 activity. In vascular models, transcriptomic profiling can connect ceramide-sensing GPCRs to atherosclerosis-related gene programs.
Disease-relevant functional models
Barrier integrity assays in intestinal epithelial cells, macrophage differentiation assays, and vascular inflammation models provide disease-relevant contexts for studying this activity [1,2,4]. Purinergic signaling in liver pathophysiology and infectious disease can be modeled in hepatocyte and immune cell systems, respectively [5,8]. Combining these functional models with genetic perturbation strengthens causal inference [4,5].
How CRISPR Can Be Used to Study GO:0045031 G protein-coupled ATP receptor activity
Knockout
CRISPR knockout of P2Y receptor genes such as P2RY11, P2RY13, and P2RY6 allows researchers to test whether a specific receptor is required for ATP-dependent G protein signaling and downstream disease phenotypes [2,3,4]. Knockout models are particularly useful for validating receptor-to-pathway links, such as P2RY13 to IL-6/STAT3 activation and mucosal barrier damage. They also help distinguish the contributions of closely related P2Y receptor subtypes.
Point Mutation
Point mutations can be introduced into receptor genes to dissect ligand-binding residues, G protein-coupling interfaces, or regulatory phosphorylation sites. Such models help determine which structural features are required for ATP binding and for GDP-to-GTP exchange on G-alpha. Point-mutation models are also useful for testing whether specific residues mediate downstream pathway selectivity.
Knock-in
Knock-in strategies can introduce tagged or variant receptors to track localization, expression, and signaling in a native genomic context. Tagged knock-in of a P2Y receptor can support imaging and biochemical purification while preserving endogenous regulation. Knock-in of disease-associated variants can help test whether a variant alters G protein-coupled ATP receptor activity.
Overexpression
Overexpression of a candidate ATP-responsive GPCR can test sufficiency for activating downstream pathways and can amplify weak signaling for detection. Overexpression models are useful when endogenous receptor levels are low or when studying receptor coupling in a defined cell background. They complement knockout studies by providing gain-of-function evidence for the same functional annotation.
How EDITGENE Supports G protein-coupled ATP receptor activity Research
Researchers studying G protein-coupled ATP receptor activity-related genes often need to determine whether a candidate gene is causally involved in ATP sensing, G protein activation, and downstream inflammatory or metabolic phenotypes. Because this activity is defined by a precise biochemical event, GDP-to-GTP exchange on G-alpha, the strongest evidence comes from combining genetic perturbation with pathway-specific functional assays. CRISPR-engineered cell models provide a controlled way to test necessity and sufficiency for genes such as P2RY11, P2RY13, and P2RY6 in disease-relevant contexts [1,2,3,4].
Contact EDITGENE today to design your custom CRISPR model for G protein-coupled ATP receptor activity research.
Frequently Asked Questions About G protein-coupled ATP receptor activity
What is GO:0045031 G protein-coupled ATP receptor activity?
GO:0045031 is a molecular function in which a receptor binds extracellular ATP and transmits the signal across the membrane by activating an associated heterotrimeric G protein, promoting GDP-to-GTP exchange on the G-alpha subunit.
What genes are involved in G protein-coupled ATP receptor activity?
Key genes include P2RY11, P2RY6, P2RY13, and other purinergic P2Y receptor family members, along with G-alpha subunits that couple to these receptors [2,3,4,5,6].
Which receptor is a human G protein-coupled ATP receptor?
P2Y11 (P2RY11) is described as a human G protein-coupled ATP receptor associated with IL-10-driven macrophage differentiation [2,3].
How does ATP activate a G protein-coupled receptor?
ATP binding promotes GDP-to-GTP exchange on the G-alpha subunit of a heterotrimeric G protein, which then engages downstream effectors.
Is G protein-coupled ATP receptor activity involved in inflammation?
Yes, P2Y11 has been linked to IL-10-driven macrophage differentiation and anti-inflammatory strategies, while P2RY13 exacerbates intestinal inflammation via IL-6/STAT3 [2,3,4].
What diseases are linked to purinergic P2Y receptors?
Purinergic P2Y receptors have been linked to atherosclerosis, intestinal inflammation, infectious disease, and liver pathophysiology [1,4,5,8].
How can I study G protein-coupled ATP receptor activity in the lab?
Common approaches include G protein activation assays, second-messenger assays, CRISPR knockout, overexpression, and transcriptomic readouts in disease-relevant cell models [2,4,6].
What is the difference between P2Y11 and P2RY13?
P2Y11 is associated with IL-10-driven macrophage differentiation, whereas P2RY13 exacerbates intestinal inflammation by activating IL-6/STAT3 and damaging the mucosal barrier [2,3,4].
Can CRISPR knockout help validate a P2Y receptor target?
Yes, CRISPR knockout of P2Y receptor genes can test whether a specific receptor is required for ATP-dependent signaling and downstream disease phenotypes [2,3,4].
Why is GO:0045031 important for drug discovery?
Because it defines a druggable GPCR function that converts extracellular ATP into intracellular G protein signals, it supports target discovery in inflammation and vascular disease [3,5,6].
Conclusion
GO:0045031, G protein-coupled ATP receptor activity, provides a precise functional definition for receptors that bind extracellular ATP and activate heterotrimeric G proteins through GDP-to-GTP exchange on G-alpha. The best-characterized human examples are purinergic P2Y receptors such as P2Y11, P2Y6, and P2Y13, which have been linked to macrophage differentiation, atherosclerosis, intestinal inflammation, infectious disease, and liver pathophysiology [1,2,3,4,5,8]. Because the function is defined by a specific biochemical event, it is well suited to causal testing with CRISPR knockout, point-mutation, knock-in, and overexpression models combined with pathway-specific assays [2,4,6]. Researchers targeting this activity can use these models to connect receptor genotype to downstream inflammatory and metabolic phenotypes in disease-relevant systems [1,4,5].
References
- 1. Zhang S et al.. 2025. Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis.. Nature 641(8062):476-485 PMID: 40049228
- 2. Gruenbacher G et al.. 2019. The Human G Protein-Coupled ATP Receptor P2Y(11) Is Associated With IL-10 Driven Macrophage Differentiation.. Front Immunol 10:1870 PMID: 31447857
- 3. Gruenbacher G et al.. 2021. The human G protein-coupled ATP receptor P2Y(11) is a target for anti-inflammatory strategies.. Br J Pharmacol 178(7):1541-1555 PMID: 33463722
- 4. Wu X et al.. 2022. P2RY13 Exacerbates Intestinal Inflammation by Damaging the Intestinal Mucosal Barrier via Activating IL-6/STAT3 Pathway.. Int J Biol Sci 18(13):5056-5069 PMID: 35982893
- 5. Carvalho LA et al.. 2025. G protein-coupled purinergic P2Y receptors in infectious diseases.. Pharmacol Ther 267:108796 PMID: 39814144
- 6. von Kügelgen I. 2019. Pharmacology of P2Y receptors.. Brain Res Bull 151:12-24 PMID: 30922852
- 8. Jain S et al.. 2021. Purinergic Signaling in Liver Pathophysiology.. Front Endocrinol (Lausanne) 12:718429 PMID: 34456873
